{
    "nctId": "NCT00795899",
    "briefTitle": "Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)",
    "officialTitle": "Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 230,
    "primaryOutcomeMeasure": "To estimate the rate of cardiac (serious) events NYHA III/IV-and pathological complete remission after study therapy.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Primary carcinoma of the breast, confirmed histologically by core biopsy (at least 3 core biopsy samples)\n2. Tumor lesion of the breast with a palpable or a imagistic size \u2265 2 cm or inflammatory breast cancer\n3. Known HER-2 status detected on core biopsy. HER-2 over expression is defined as DAKO HercepTest (3+) or DAKO HercepTest (2+) and FISH (+) (fluorescence-in-situ-hybridisation).\n4. No distant metastatic disease, confirmed by chest x-ray, abdominal sonography and bone scan.\n5. Female patients\n6. Age \u2265 18 and \u2264 65 years\n7. ECOG \\< 2/WHO 0-1\n8. Laboratory requirements GOT and Bilirubin \\< 1.5x UNL Leukocytes \\>= 3 G/l Neutrophile \\> 1 G/l Thrombocytes \\> 100 G/l Creatinine (Serum) \\< 2.0 mg/dl.\n9. Normal cardiac function, confirmed by cardiologist\n10. No active hepatitis\n11. Written informed consent for all study procedures\n12. Patients must be available and compliant for treatment and follow-up\n\nExclusion Criteria:\n\n1. Multicentricity in various quadrants (contact the study office)\n2. CNS-metastases\n3. Secondary malignancy, excluding basalioma of the skin or carcinoma in situ of the cervix that has received curative therapy\n4. Patients with relevant hemodynamic cardial diseases\n5. Patients with a left ventricular ejection fraction (LVEF) under the normal limit of the institution, confirmed by echocardiography or MUGA-Scan.\n6. Uncontrolled, severe comorbidities\n7. Patients with severe respiratory diseases and severe dyspnea and / or which need supportive oxygen\n8. Previous anti-HER2-therapy\n9. Patients receiving immunosuppressant therapy\n10. Known allergy to medication containing cremophor\n11. Hb \\<10 g/dL, Neutrophile \\<1.5 x109/L, Thrombocytes \\<100 x109/L.\n12. Total-Serum-Bilirubin \\>1.5 x ULN (upper limit of normal) (except in patients with confirmed and documented Gilbert-Lereboullet-syndrome), ALT or AST \\>2.5 x ULN (\\>5 x ULN by liver metastases), Alkaline Phosphatase \\>2.5 x ULN (\\>4 x ULN by liver or bone metastases), Serumcreatinine \\> 2 x ULN\n13. Pregnancy, nursing (a negative pregnancy test must be documented, and safe anticontraceptive measures during pre- and postoperative treatment must be implemented)\n14. Lack of signed informed consent after informing the patient\n15. Lack of willingness to keep and disclose personal medical data as part of the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}